Extensive Bruising and Elevated Rivaroxaban Plasma Concentration in a Patient Receiving Cobicistat-Boosted Elvitegravir

Abstract

Get full access to this article

View all access options for this article.

References

Mueck

Kubitza

Becka

Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol. 2013;76:455-466.

Gordon

Kumar

Brooks

. Antiretroviral boosting agent cobicistat increases the pharmacokinetic exposure and anticoagulant effect of dabigatran in HIV-negative health volunteers. Circulation. 2016;134:1909-1911.

Egan

Hughes

Ackman

ML.

Drug interactions between antiplatelet or novel oral anticoagulant medications and antiretroviral medications. Ann Pharmacother. 2014;48:734-740.

Corallo

Grannell

Tran

Postoperative bleeding after administration of a single dose of rivaroxaban to a patient receiving antiretroviral therapy. Drug Saf. 2015; 2:11.

Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences; 2016.

Heidbuchel

Verhamme

Alings

. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17:1467-1507.

Mueck

Lensing

Agnelli

Decousus

Prandoni

Misselwitz

Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmcokinet. 2011;50:675-686.

Horn

Hansen

Chan

LN.

Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother. 2007;41:674-680.